IGXT (Mkap $34 M) 2 US-Zulassungsanträge im 4Q + weiteres Produkt wartet auf FDA Zulassung (Seite 32)
eröffnet am 27.07.16 17:27:05 von
neuester Beitrag 21.03.24 14:04:18 von
neuester Beitrag 21.03.24 14:04:18 von
Beiträge: 1.197
ID: 1.235.830
ID: 1.235.830
Aufrufe heute: 0
Gesamt: 195.654
Gesamt: 195.654
Aktive User: 0
ISIN: US45822R1014 · WKN: A0RP0X
0,1490
EUR
+1,36 %
+0,0020 EUR
Letzter Kurs 24.04.24 L&S Exchange
Neuigkeiten
08.04.24 · globenewswire  |
05.04.24 · globenewswire |
21.03.24 · globenewswire |
14.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8300 | +161,43 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 | |
| 1,0900 | +14,74 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,2400 | -9,59 | |
| 0,5058 | -12,79 | |
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 61.211.438 von Steel21x am 08.08.19 23:11:36Dankeschön für die Infos. Dann heißt wohl weiter warten warten warten......
Habe mal in den CC reingehört.
Also Tadalafil verzögert sich weiter. Erwartete Zulassung Anfang 2021.
Cannabis Films könnten Ende 2019 Anfang 2020 erste Umsätze geben.
Refiling von Rizaport in den USA noch in diesem Quartal.
Rizaport Europa wird wohl noch dauern.
Also Tadalafil verzögert sich weiter. Erwartete Zulassung Anfang 2021.
Cannabis Films könnten Ende 2019 Anfang 2020 erste Umsätze geben.
Refiling von Rizaport in den USA noch in diesem Quartal.
Rizaport Europa wird wohl noch dauern.
Antwort auf Beitrag Nr.: 61.204.625 von huba1972 am 08.08.19 09:55:18wann gab es denn zuletzt einen Anstieg!?!?!?!
https://mailchi.mp/eb174273445b/intelgenx-to-present-at-12th…
Schaut nicht nach nem Burner aus...
https://mailchi.mp/eb174273445b/intelgenx-to-present-at-12th…
Schaut nicht nach nem Burner aus...
Was ist den hier los ? Absturz ?
Eher enttäuschend mal wieder.Anscheinend kein Upfront, 10% Royalties für Rizaport da anscheinend die eigene Technologie nicht ausreicht um die Genehmigung der FDA zu bekommen.
Trading Spotlight
IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Kopie, kompletter Inhalt aus fremden Medien, Urheberrechtsverletzung, zudem ohne Quellenangabe bzw URL!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Löschung auf Wunsch des Users
IntelGenx files U.S. patent for oral film platform
2019-04-16 08:13 ET - News Release
Dr. Horst Zerbe reports
INTELGENX FILES NON-PROVISIONAL U.S. PATENT APPLICATION FOR OIL-BASED ACTIVE INGREDIENTS
IntelGenx Technologies Corp. has filed a new non-provisional patent application at the U.S. Patent and Trademark Office entitled "Lipophilic Active Oral Film Formulation And Method Of Making The Same."
The patent application covers a newly developed platform that enables the incorporation of oil-based (lipophilic) active ingredients into oral film formulations. This new platform, suitable for both VersaFilm and VetaFilm, is compatible with several of IntelGenx's current projects including Montelukast, Loxapine and cannabis-infused films. The technology may also be used when more than one active ingredients, such as THC (tetrahydrocannabinol) and CBD (cannabidiol), are applied in a single film product.
"This new filing adds to the global intellectual property estate that we are building for VersaFilm and VetaFilm," said Dr. Horst G. Zerbe, president and chief executive officer of IntelGenx. "We anticipate that this application will also be filed in several other international jurisdictions as the application progresses in the United States."
About IntelGenx Technologies Corp.
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm technology platform.
We seek Safe Harbor
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aIGX-2744…
2019-04-16 08:13 ET - News Release
Dr. Horst Zerbe reports
INTELGENX FILES NON-PROVISIONAL U.S. PATENT APPLICATION FOR OIL-BASED ACTIVE INGREDIENTS
IntelGenx Technologies Corp. has filed a new non-provisional patent application at the U.S. Patent and Trademark Office entitled "Lipophilic Active Oral Film Formulation And Method Of Making The Same."
The patent application covers a newly developed platform that enables the incorporation of oil-based (lipophilic) active ingredients into oral film formulations. This new platform, suitable for both VersaFilm and VetaFilm, is compatible with several of IntelGenx's current projects including Montelukast, Loxapine and cannabis-infused films. The technology may also be used when more than one active ingredients, such as THC (tetrahydrocannabinol) and CBD (cannabidiol), are applied in a single film product.
"This new filing adds to the global intellectual property estate that we are building for VersaFilm and VetaFilm," said Dr. Horst G. Zerbe, president and chief executive officer of IntelGenx. "We anticipate that this application will also be filed in several other international jurisdictions as the application progresses in the United States."
About IntelGenx Technologies Corp.
Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm technology platform.
We seek Safe Harbor
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aIGX-2744…
Durchsuchen
